CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 429 enrolled
Drug / intervention
Abciximab +1 moredrug
Likely dose
Abciximab 0.25 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00426751
NCT00426751Phase 3Completed
CompareCT.gov

Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction

GlaxoSmithKline·interventional·Posted Jan 25, 2007·Updated Nov 27, 2012

In Brief

A Phase 3 clinical trial evaluating Abciximab and Eptifibatide for Infarction, Myocardial. Completed, enrolled 429 participants across 24 sites in 2 countries.

Detailed Summary

Multinational, multicentre, randomised, prospective, open, parallel group study directly comparing two glycoprotein-IIb/IIIa inhibitors, abciximab and eptifibatide, added early to standard treatment before primary PCI of STEMI patients with respect to effect on sum-ST-resolution after 60 minutes post-procedure and other measures of myocardial reperfusion

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfarction, Myocardial
CountriesFrance, Germany
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 25, 2007
Enrollment StartOct 1, 2006
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.4 years ago

Interventions

Abciximabdrug

Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.

Eptifibatidedrug

Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.